Loading
A phase 3 trial of BGB-16673, Bendamustine, Rituximab, Chlorambucil and Obinutuzumab in chronic lymphocytic leukaemia, run by BeOne Medicines, active and no longer recruiting.
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors is a phase 3 interventional study registered as NCT06970743 by BeOne Medicines, with 153 participants enrolled, started 2025-05-29 and due to reach its primary completion in 2029-11-30. Interventions recorded: BGB-16673, Bendamustine, Rituximab, Methylprednisolone, Chlorambucil and Obinutuzumab.
Shares Obinutuzumab, Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene), Rituximab and the tag pipeline.
Shares Bendamustine, Relapsed or refractory chronic lymphocytic leukaemia, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
Shares Bendamustine, BeOne Medicines (formerly BeiGene), Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chlorambucil, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Bendamustine, Obinutuzumab, Rituximab and the tag pipeline.